| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/10/2008 | WO2007130785A3 Materials and methods for treating pneumocystis pneumonia |
| 04/10/2008 | WO2007130725A3 Use of hmgb1 for protection against ischemia reperfusion injury |
| 04/10/2008 | WO2007127428A8 Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
| 04/10/2008 | WO2007118292A3 MEMBRANE PROTEIN Sm29 OF SCHISTOSOMA MANSONI AND USES THEREOF FOR TREATING AND DIAGNOSING SCHISTOSOMIASIS |
| 04/10/2008 | WO2007107587A3 Cholesterol lowering protein hydrolysates |
| 04/10/2008 | WO2007103523A9 Antioxidant protein, compositions, and methods of use |
| 04/10/2008 | WO2007100833A3 Gpat4 encodes a mammalian, microsomal acyl-coa:glycerol 3-phosphate acyltransferase |
| 04/10/2008 | WO2007096199A3 Differential diagnostics and therapy of virally induced heart muscle disease |
| 04/10/2008 | WO2007089445A3 Ang2 and vegf inhibitor combinations |
| 04/10/2008 | WO2007075342A3 Vaccine adjuvant |
| 04/10/2008 | WO2007070392A3 Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
| 04/10/2008 | WO2007070385A3 Treatment of multiple sclerosis using interferon-tau |
| 04/10/2008 | WO2007068240A3 Peptides interacting with alpha-helical coiled-coil structures and/or coiled-coil sequences, substances derived therefrom, and use thereof |
| 04/10/2008 | WO2007056681A3 Methods for administering hypoglycemic agents |
| 04/10/2008 | WO2007047430A8 Method of treating acute failure with thrombomodulin variant |
| 04/10/2008 | WO2006138466B1 Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules |
| 04/10/2008 | WO2004100892A3 Novel fibroblast growth factors and methods of use thereof |
| 04/10/2008 | US20080086016 lisdexamfetamine, lisdexamfetamine dimesylate and lisdexamfetamine hydrochloride; attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity |
| 04/10/2008 | US20080085999 Modulation of gene expression using dna-rna hybrids |
| 04/10/2008 | US20080085995 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/10/2008 | US20080085866 Metallo-desferrioxamine complexes and their use in the treatment of bacterial infections |
| 04/10/2008 | US20080085865 Factor c for treating gram-negative bacterial infection |
| 04/10/2008 | US20080085864 Method of modifying glucose activity using polypeptides selectively expressed in fat tissue |
| 04/10/2008 | US20080085863 Method and Composition for Treating a Fibrotic Disorder |
| 04/10/2008 | US20080085862 Natriuretic peptide conjugate using carrier substance |
| 04/10/2008 | US20080085861 Gas1 polypeptides |
| 04/10/2008 | US20080085860 Selective Vpac2 Receptor Peptide Agonists |
| 04/10/2008 | US20080085859 Drug Promoting Ceramide Transport, Base Sequence for Producing the Drug, Method of Measuring Activity of Promoting Ceramide Release and Method of Measuring Activity of Promoting Intermembrane Ceramide Transfer |
| 04/10/2008 | US20080085858 Pharmaceutical Composition |
| 04/10/2008 | US20080085857 conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 |
| 04/10/2008 | US20080085855 or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described.microtubule stabilizing agents, anti-angiogenic factors, inhibitors of smooth muscle cell growth or proliferation, |
| 04/10/2008 | US20080085854 Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors |
| 04/10/2008 | US20080085853 nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; |
| 04/10/2008 | US20080085852 Use of Xikvav Peptides in the Preparation of Cosmetic Compositions Which are Intented to Improve the Firmness of the Skin by Increasing Cell Adhesion |
| 04/10/2008 | US20080085323 Promotes myoblast differentiation based on identification of cellular processes affected by prelamin A processing |
| 04/10/2008 | US20080085302 Administering a time-dependent antimicrobial drug transdermally to achieve a serum concentration that remains above the minimum inhibitory concentration (MIC) of the drug consistantly to reduce risk of drug resistance and gastrointstinal side effects; zero order kinetics; shortened therapy duration |
| 04/10/2008 | US20080085301 Method for transdermal administration of antimicrobial medications |
| 04/10/2008 | US20080085299 Peptides derived from colostrinin |
| 04/10/2008 | US20080085298 administering insulin, a dissolution agent and a zinc chelator to a mucosal surface, preferably the mouth or under the tongue; enhanced uptake and transport through epithelial cells as compared to insulin alone or with a zinc chelator and hydrochloric acid in a gel, film, powder or patch; stability |
| 04/10/2008 | US20080085289 An immunogenic composition comprising Staphylococcal poly-N-acetylglucosamine (PNAG) and Type 8 capsular polysaccharide or oligosaccharide from Staph aureus; vaccines; e.g., mixture of a Staph extracellular component binding protein and a staph transporter protein, regulator of virulence or toxin |
| 04/10/2008 | US20080085281 Using modulators of Dickkopf homolog 1 (DKK-1) activity as tool in treatment and prevention of osteolytic lesion; wnt signaling antagonist; antitumor agents |
| 04/10/2008 | US20080085275 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 04/10/2008 | US20080085274 Using tumor necrosis factor modulators/inhibitors as tool in treatment and prevention of spinal cord injury |
| 04/10/2008 | US20080085273 Vehicle for the transport of a chosen molecule to a cell |
| 04/10/2008 | US20080085272 Encapsulating therapeutic agent in spider silk fibroin; contolling release of pharmaceutical agents |
| 04/10/2008 | US20080085271 Methods of preventing or treating cell-migration mediated conditions or diseases |
| 04/10/2008 | US20080085270 Mixture comprising g-gamma tocopherol, tocotrienol, black pepper extract and ubiquinone for use in treatment of cardiovascular disorders |
| 04/10/2008 | US20080085269 Vaccine And Method For Treatment Of Neurodegenerative Diseases |
| 04/10/2008 | US20080085266 Using cancer antigen 125 as tool in generating transmembrane serine protease inhibitory compound for treatment of urogenital cell proliferative disorders |
| 04/10/2008 | US20080085264 Targeting progenitor cells to bone marrow for prevention and treatment of cell proliferative disorders; regenerative medicine and tissue engineering |
| 04/10/2008 | US20080085262 Purified mammalian cytokines; related reagents and methods |
| 04/10/2008 | US20080085261 Vaccine Adjuvant |
| 04/10/2008 | DE102006047529A1 Dermatological composition contains an oligopeptide as an agent for increasing skin sensitivity |
| 04/10/2008 | DE10066235B4 Targeted inhibition of gene expression by administration of double stranded oligoribonucleotide to a cell, useful for treating humans, animals and plants against viral infection |
| 04/10/2008 | CA2665904A1 Peptides derived from the c2 domain of .epsilon.pkc and methods of use, thereof |
| 04/10/2008 | CA2665689A1 Glutathione preparation and method for production thereof |
| 04/10/2008 | CA2665531A1 Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme |
| 04/10/2008 | CA2665351A1 Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| 04/10/2008 | CA2665269A1 Antibacterial and antiviral peptides from actinomadura namibiensis |
| 04/10/2008 | CA2665117A1 Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy |
| 04/10/2008 | CA2665037A1 Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions |
| 04/10/2008 | CA2664743A1 Methods of treating hyperandrogenism and conditions associated therewith by administering a fatty acid ester of an estrogen or an estrogen derivative |
| 04/10/2008 | CA2664637A1 Dried reconstituted vesicle formation for pharmaceutical application |
| 04/10/2008 | CA2653628A1 Neuroactive fragments of app |
| 04/09/2008 | EP1908839A2 Virulence genes, proteins, and their use |
| 04/09/2008 | EP1908837A2 Human receptor proteins, related reagents and methods |
| 04/09/2008 | EP1908836A1 Novel G protein-coupled receptor proteins |
| 04/09/2008 | EP1908834A2 Heteromultimeric ion channel receptor and uses thereof |
| 04/09/2008 | EP1908830A1 Non-human gene-disrupted animal having adam11 gene disruption |
| 04/09/2008 | EP1908827A2 Regulation of cardiac contractility and heart failure propensity |
| 04/09/2008 | EP1908823A1 Component of bromelain |
| 04/09/2008 | EP1908782A1 Human coagulation factor VII polypeptides |
| 04/09/2008 | EP1908781A2 Modulation of immune response and methods based thereon |
| 04/09/2008 | EP1908780A1 Novel chimeric proteins and methods for using the same |
| 04/09/2008 | EP1908779A1 Thymosin beta 4 derivatives and use thereof |
| 04/09/2008 | EP1908777A1 Mite fusion proteins |
| 04/09/2008 | EP1908776A1 Mite fusion proteins |
| 04/09/2008 | EP1908774A1 Antibacterial and antiviral peptides from Actinomadura namibiensis |
| 04/09/2008 | EP1908772A2 Porphorymonas gingivalis polypeptides and polynucleotides |
| 04/09/2008 | EP1908770A1 Methods for preparing purified lipopeptides |
| 04/09/2008 | EP1908490A1 Biodegradable, anionic polymers derived from the aminoacid l-tyrosine |
| 04/09/2008 | EP1908479A2 Anti-p53 Antibodies |
| 04/09/2008 | EP1908478A1 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation |
| 04/09/2008 | EP1908477A2 Combination of temozolomide and pegylated interferon-alpha for treating cancer |
| 04/09/2008 | EP1908476A1 Galectin-2 for the treatment of inflammatory diseases of the skin |
| 04/09/2008 | EP1908475A1 Use of anti-prolactin agents to treat cancer |
| 04/09/2008 | EP1908463A2 Methods of inducing ovulation using a non-polypeptide camp level modulator |
| 04/09/2008 | EP1908462A2 Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| 04/09/2008 | EP1908449A1 Sterilizer selective to cariogenic bacterium, and method for sterilization of cariogenic bacterium |
| 04/09/2008 | EP1908354A1 Process for production of fermented milk and fermented milk beverage/food |
| 04/09/2008 | EP1907852A2 Stable quantitation and detection of immune response levels with non-zero background peptides |
| 04/09/2008 | EP1907842A1 Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha |
| 04/09/2008 | EP1907419A1 Preparation of insulin conjugates |
| 04/09/2008 | EP1907418A2 Heterodimeric four helix bundle cytokines |
| 04/09/2008 | EP1907417A2 Supravalent compounds |
| 04/09/2008 | EP1907413A2 Antibacterial amide macrocycles vii |
| 04/09/2008 | EP1907412A2 Peptides inhibiting angiotensin-converting enzyme |
| 04/09/2008 | EP1907403A2 Antiviral compounds |
| 04/09/2008 | EP1907022A2 Compositions for topical enzymatic debridement |
| 04/09/2008 | EP1907008A2 Formulations for enhanced mucosal delivery of pyy |